drugset / Trial / NCT00896558

A Repeat Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK1322322 in Healthy Subjects

NCT00896558

Phase 1 Completed 52 enrolled GlaxoSmithKline
RandomizedSingle-groupTriple-blindTreatment

Summary

This study will be the first repeat dose administration of GSK1322322 to investigate safety, tolerability, and pharmacokinetics in healthy subjects as well as elderly volunteer subjects. The study will also include a P450 probe drug (midazolam) to evaluate the effect of GSK1322322 to inhibit or induce CYP3A4 substrates.

Timeline

Start
2009-05-11
Primary completion
2009-09-25
Completion
2009-09-25

Drugs

EvaluationDrugModalityDoseRoute
Subject LANOPEPDEN Small molecule 500 mg
Subject LANOPEPDEN Small molecule 1500 mg
Subject Midazolam Small molecule 5 mg